Literature DB >> 28576843

Targeting BRAF-Mutant Colorectal Cancer: Progress in Combination Strategies.

Raghav Sundar1,2, David S Hong3, Scott Kopetz3, Timothy A Yap4.   

Abstract

<b/> BRAF mutations in colorectal cancer portend a poor prognosis, with first-line treatment often involving triplet or quadruplet chemotherapy, and single-agent targeted therapy with BRAF inhibitors failing to demonstrate clinical activity. Blockade of multiple critical nodes along the MAPK and other pathways may be necessary to improve response rates and survival. Cancer Discov; 7(6); 558-60. ©2017 AACR.See related article by van Geel et al., p. 610. ©2017 American Association for Cancer Research.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28576843      PMCID： PMC5458523          DOI： 10.1158/2159-8290.CD-17-0087

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  10 in total

1.  Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.

Authors:  Anirudh Prahallad; Chong Sun; Sidong Huang; Federica Di Nicolantonio; Ramon Salazar; Davide Zecchin; Roderick L Beijersbergen; Alberto Bardelli; René Bernards
Journal:  Nature       Date:  2012-01-26       Impact factor: 49.962

2.  Pilot trial of combined BRAF and EGFR inhibition in BRAF-mutant metastatic colorectal cancer patients.

Authors:  Rona Yaeger; Andrea Cercek; Eileen M O'Reilly; Diane L Reidy; Nancy Kemeny; Tamar Wolinsky; Marinela Capanu; Marc J Gollub; Neal Rosen; Michael F Berger; Mario E Lacouture; Efsevia Vakiani; Leonard B Saltz
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

3.  Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer.

Authors:  Ryan B Corcoran; Chloe E Atreya; Gerald S Falchook; Eunice L Kwak; David P Ryan; Johanna C Bendell; Omid Hamid; Wells A Messersmith; Adil Daud; Razelle Kurzrock; Mariaelena Pierobon; Peng Sun; Elizabeth Cunningham; Shonda Little; Keith Orford; Monica Motwani; Yuchen Bai; Kiran Patel; Alan P Venook; Scott Kopetz
Journal:  J Clin Oncol       Date:  2015-09-21       Impact factor: 44.544

4.  A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

Authors:  Robin M J M van Geel; Josep Tabernero; Elena Elez; Johanna C Bendell; Anna Spreafico; Martin Schuler; Takayuki Yoshino; Jean-Pierre Delord; Yasuhide Yamada; Martijn P Lolkema; Jason E Faris; Ferry A L M Eskens; Sunil Sharma; Rona Yaeger; Heinz-Josef Lenz; Zev A Wainberg; Emin Avsar; Arkendu Chatterjee; Savina Jaeger; Eugene Tan; Kati Maharry; Tim Demuth; Jan H M Schellens
Journal:  Cancer Discov       Date:  2017-03-31       Impact factor: 39.397

5.  Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAFV600E Mutation.

Authors:  David S Hong; Van K Morris; Badi El Osta; Alexey V Sorokin; Filip Janku; Siqing Fu; Michael J Overman; Sarina Piha-Paul; Vivek Subbiah; Bryan Kee; Apostolia M Tsimberidou; David Fogelman; Jorge Bellido; Imad Shureiqi; Helen Huang; Johnique Atkins; Gabi Tarcic; Nicolas Sommer; Richard Lanman; Funda Meric-Bernstam; Scott Kopetz
Journal:  Cancer Discov       Date:  2016-10-11       Impact factor: 39.397

6.  Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.

Authors:  Muling Mao; Feng Tian; John M Mariadason; Chun C Tsao; Robert Lemos; Farshid Dayyani; Y N Vashisht Gopal; Zhi-Qin Jiang; Ignacio I Wistuba; Xi M Tang; William G Bornman; Gideon Bollag; Gordon B Mills; Garth Powis; Jayesh Desai; Gary E Gallick; Michael A Davies; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2012-12-18       Impact factor: 12.531

7.  Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations.

Authors:  David M Hyman; Igor Puzanov; Vivek Subbiah; Jason E Faris; Ian Chau; Jean-Yves Blay; Jürgen Wolf; Noopur S Raje; Eli L Diamond; Antoine Hollebecque; Radj Gervais; Maria Elena Elez-Fernandez; Antoine Italiano; Ralf-Dieter Hofheinz; Manuel Hidalgo; Emily Chan; Martin Schuler; Susan Frances Lasserre; Martina Makrutzki; Florin Sirzen; Maria Luisa Veronese; Josep Tabernero; José Baselga
Journal:  N Engl J Med       Date:  2015-08-20       Impact factor: 91.245

8.  Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.

Authors:  Daniele Oddo; Erin M Sennott; Ludovic Barault; Emanuele Valtorta; Sabrina Arena; Andrea Cassingena; Genny Filiciotto; Giulia Marzolla; Elena Elez; Robin M J M van Geel; Alice Bartolini; Giovanni Crisafulli; Valentina Boscaro; Jason T Godfrey; Michela Buscarino; Carlotta Cancelliere; Michael Linnebacher; Giorgio Corti; Mauro Truini; Giulia Siravegna; Julieta Grasselli; Margherita Gallicchio; René Bernards; Jan H M Schellens; Josep Tabernero; Jeffrey A Engelman; Andrea Sartore-Bianchi; Alberto Bardelli; Salvatore Siena; Ryan B Corcoran; Federica Di Nicolantonio
Journal:  Cancer Res       Date:  2016-06-16       Impact factor: 12.701

Review 9.  Are Doses and Schedules of Small-Molecule Targeted Anticancer Drugs Recommended by Phase I Studies Realistic?

Authors:  Desamparados Roda; Begoña Jimenez; Udai Banerji
Journal:  Clin Cancer Res       Date:  2015-11-18       Impact factor: 12.531

10.  Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer.

Authors:  Scott Kopetz; Jayesh Desai; Emily Chan; Joel Randolph Hecht; Peter J O'Dwyer; Dipen Maru; Van Morris; Filip Janku; Arvind Dasari; Woonbook Chung; Jean-Pierre J Issa; Peter Gibbs; Brian James; Garth Powis; Keith B Nolop; Suman Bhattacharya; Leonard Saltz
Journal:  J Clin Oncol       Date:  2015-10-12       Impact factor: 44.544
  10 in total
  10 in total

1.  BRAF inhibition upregulates a variety of receptor tyrosine kinases and their downstream effector Gab2 in colorectal cancer cell lines.

Authors:  Ricarda Herr; Sebastian Halbach; Miriam Heizmann; Hauke Busch; Melanie Boerries; Tilman Brummer
Journal:  Oncogene       Date:  2018-01-12       Impact factor: 9.867

2.  A System-wide Approach to Monitor Responses to Synergistic BRAF and EGFR Inhibition in Colorectal Cancer Cells.

Authors:  Anna Ressa; Evert Bosdriesz; Joep de Ligt; Sara Mainardi; Gianluca Maddalo; Anirudh Prahallad; Myrthe Jager; Lisanne de la Fonteijne; Martin Fitzpatrick; Stijn Groten; A F Maarten Altelaar; René Bernards; Edwin Cuppen; Lodewyk Wessels; Albert J R Heck
Journal:  Mol Cell Proteomics       Date:  2018-07-03       Impact factor: 5.911

Review 3.  Promising New Agents for Colorectal Cancer.

Authors:  Satya Das; Kristen K Ciombor; Sigurdis Haraldsdottir; Richard M Goldberg
Journal:  Curr Treat Options Oncol       Date:  2018-05-11

4.  Can CT-based radiomics signature predict KRAS/NRAS/BRAF mutations in colorectal cancer?

Authors:  Lei Yang; Di Dong; Mengjie Fang; Yongbei Zhu; Yali Zang; Zhenyu Liu; Hongmei Zhang; Jianming Ying; Xinming Zhao; Jie Tian
Journal:  Eur Radiol       Date:  2018-01-15       Impact factor: 5.315

Review 5.  The application of radiomics in predicting gene mutations in cancer.

Authors:  Yana Qi; Tingting Zhao; Mingyong Han
Journal:  Eur Radiol       Date:  2022-01-20       Impact factor: 5.315

6.  Novel putative drivers revealed by targeted exome sequencing of advanced solid tumors.

Authors:  Antonio Pannuti; Aleksandra Filipovic; Chindo Hicks; Elliot Lefkowitz; Travis Ptacek; Justin Stebbing; Lucio Miele
Journal:  PLoS One       Date:  2018-03-23       Impact factor: 3.240

Review 7.  Development of small-molecule therapeutics and strategies for targeting RAF kinase in BRAF-mutant colorectal cancer.

Authors:  Jing-Hua Pan; Hong Zhou; Sheng-Bin Zhu; Jin-Lian Huang; Xiao-Xu Zhao; Hui Ding; Yun-Long Pan
Journal:  Cancer Manag Res       Date:  2018-08-01       Impact factor: 3.989

8.  Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies.

Authors:  Mariangela Russo; Simona Lamba; Annalisa Lorenzato; Alberto Sogari; Giorgio Corti; Giuseppe Rospo; Benedetta Mussolin; Monica Montone; Luca Lazzari; Sabrina Arena; Daniele Oddo; Michael Linnebacher; Andrea Sartore-Bianchi; Filippo Pietrantonio; Salvatore Siena; Federica Di Nicolantonio; Alberto Bardelli
Journal:  Nat Commun       Date:  2018-06-12       Impact factor: 14.919

9.  BRAFV600E drives dedifferentiation in small intestinal and colonic organoids and cooperates with mutant p53 and Apc loss in transformation.

Authors:  Nadine Reischmann; Geoffroy Andrieux; Ricarda Griffin; Thomas Reinheckel; Melanie Boerries; Tilman Brummer
Journal:  Oncogene       Date:  2020-08-13       Impact factor: 9.867

10.  Spatial profiling of gastric cancer patient-matched primary and locoregional metastases reveals principles of tumour dissemination.

Authors:  Raghav Sundar; Drolaiz Hw Liu; Gordon Ga Hutchins; Hayley L Slaney; Arnaldo Ns Silva; Jan Oosting; Jeremy D Hayden; Lindsay C Hewitt; Cedric Cy Ng; Amrita Mangalvedhekar; Sarah B Ng; Iain Bh Tan; Patrick Tan; Heike I Grabsch
Journal:  Gut       Date:  2020-11-23       Impact factor: 23.059
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.